Progression of regional atrophy in the left hemisphere contributes to clinical and cognitive deterioration in

Paolo Preziosa1,2, Elisabetta Pagani1, Sarlota Mesaros3

  • 1Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Human Brain Mapping
|August 10, 2017
PubMed

Insights

Multiple sclerosis patients show significant gray and white matter atrophy over five years, linked to worsening disability and cognition. A left-hemisphere vulnerability may drive these clinical declines.

Area of Science:

  • Neuroimaging
  • Neurology
  • Brain Research

Background:

  • Multiple sclerosis (MS) is a chronic demyelinating disease characterized by focal lesions and progressive neurodegeneration.
  • Understanding the longitudinal patterns of brain atrophy and their clinical correlations is crucial for MS management.

Purpose of the Study:

  • To investigate regional gray matter (GM) and white matter (WM) atrophy progression over five years in MS patients.
  • To associate these structural changes with clinical and cognitive deterioration.

Main Methods:

  • Longitudinal study with 66 MS patients and 16 controls, assessed at baseline and after a median 4.9-year follow-up.
  • Brain MRI (dual-echo, 3D T1-weighted) and neurological/neuropsychological assessments.
  • Analysis using lesion probability maps, tensor-based morphometry, and SPM12.

Main Results:

  • At follow-up, 54.5% of MS patients showed worsening disability, 21.2% evolved to a worse clinical phenotype, and 28.6% experienced cognitive decline.
  • MS patients exhibited widespread GM and WM atrophy at baseline, progressing significantly over five years.
  • Patients with clinical and cognitive worsening displayed a left-lateralized pattern of GM and WM atrophy.

Conclusions:

  • Significant GM and WM atrophy occurs in MS patients within five years.
  • A differential vulnerability of brain hemispheres to structural damage may contribute to clinical and cognitive worsening in MS.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
973
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K